TRADING UPDATES: Shield closer to Canada approval; Angle plans raise
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read moreMon, 21st Mar 2016 14:04
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read more(Sharecast News) - Liquid biopsy company Angle has secured an additional contract with its first large-scale pharmaceutical services customer.
Read more(Alliance News) - Angle PLC on Wednesday said it has secured further business with its "first large scale pharma services" customer.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read moreAngle PLC - Surrey, England-based medical diagnostics company - Notes researchers at King's College London published data investigating the role of invasive cellular protrusion, known as invadopodia, activity in prostate cancer, and a potential role in the formation of circulating tumour cells. Researchers used Angle's Parsortix system's ability to isolate CTCs from the blood of prostate cancer patients. Parsortix system isolates CTCs in 94% of prostate cancer patients, showing some association with matrix degradation and invasive cellular protrusion formation. This may allow novel therapeutic development targeting the mechanisms of invadopodia and reducing metastatic spread of the cancer, it says.
Read moreAngle PLC - Surrey, England-based medical diagnostics company - Establishes partnership with MidLantic Urology to evaluate the use of its Parasortix system in prostate cancer clinical studies. MidLantic is as an affiliate of special urology services provider Solaris, which has over 500 clinical urology providers across 179 locations in the US, with over 729,000 annual patients. Angle hopes the collaboration will "enable potential sales" to Solaris' patient base. The first study is expected to start in the third quarter of 2022, with results to be available in 2023.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:
Read moreAngle PLC - Surrey, England-based medical diagnostics company - Receives approval from the US Food & Drug Administration for the use of its Parasortix system for use in metastatic breast cancer patients. Parasortix isolates circulating tumour cells from the blood which can aid in the diagnosis, characterisation and monitoring of cancer, and do so in a much less invasive fashion than traditional tissue biospy.
Read more(Alliance News) - Stocks in London ended mostly higher on Wednesday as market participants look ahead to the latest minutes from the US Federal Reserve at 1900 BST.
Read more(Sharecast News) - Liquid biopsy company Angle announced on Friday that Prostate Cancer UK has approved funding for a "significant" clinical study at the Barts Cancer Institute of the Queen Mary University of London.
Read moreAngle PLC - Surrey, England-based medical diagnostics company - Says Prostate Cancer UK has given a GBP750,000 grant for a clinical study at Barts Cancer Institute, Queen Mary University of London. The trial will follow 200 men with localised prostate cancer over five years, assessed using Angle's Parsortix system, in bid to see whether the cancer will eventually spread.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read moreFriday 22 April | |
Alphawave IP Group PLC | Full Year Results |
Petropavlovsk PLC | Trading Statement |
Record PLC | Trading Statement |
Serabi Gold PLC | Full Year Results |
Zinc Media Group PLC | Full Year Results |
Monday 25 April | |
Access Intelligence PLC | Full Year Results |
Arecor Therapeutics PLC | Full Year Results |
Audioboom Group PLC | Full Year Results |
CentralNic Group PLC | Trading Statement |
Chapel Down Group PLC | Full Year Results |
Lok'n Store Group PLC | Half Year Results |
Vector Capital PLC | Full Year Results |
Tuesday 26 April | |
ASA International Group PLC | Full Year Results |
Associated British Foods PLC | Half Year Results |
Billington Holdings PLC | Full Year Results |
Corero Network Security PLC | Full Year Results |
Focusrite PLC | Half Year Results |
Futura Medical PLC | Full Year Results |
Gaming Realms PLC | Full Year Results |
Hochschild Mining PLC | Trading Statement |
HSBC Holdings PLC | Q1 Results (at 0500 BST) |
Immotion Group PLC | Full Year Results |
IWG PLC | Trading Statement |
Jupiter Fund Management PLC | Trading Statement |
Learning Technologies Group PLC | Full Year Results |
Loungers PLC | Trading Statement |
National Express Group PLC | Trading Statement |
Northcoders Group PLC | Full Year Results |
Nostrum Oil & Gas PLC | Full Year Results |
PureTech Health PLC | Full Year Results |
RWS Holdings PLC | Half Year Results |
Taylor Wimpey PLC | Full Year Results |
Wednesday 27 April | |
1Spatial PLC | Full Year Results |
AB Dynamics PLC | Half Year Results |
Anglo Pacific Group PLC | Q1 Results |
Aveva Group PLC | Trading Statement |
City Pub Group PLC | Full Year Results |
Drax Group PLC | Trading Statement |
Fresnillo PLC | Q1 Production Results |
GlaxoSmithKline PLC | Q1 Results |
Go-Ahead Group PLC | Half Year Results |
Lloyds Banking Group PLC | Q1 Results |
London Stock Exchange Group PLC | Trading Statement |
Network International Holdings PLC | Trading Statement |
Nichols PLC | Full Year Results |
Persimmon PLC | Trading Statement |
Primary Health Properties PLC | Trading Statement |
RPS Group PLC | Q1 Results |
WH Smith PLC | Half Year Results |
WPP PLC | Trading Statement |
Yamana Gold Inc | Trading Statement |
Thursday 28 April | |
Angle PLC | Full Year Results |
Barclays PLC | Q1 Results |
Brave Bison Group PLC | Full Year Results |
C4X Discovery Holdings PLC | Half Year Results |
Evraz PLC | Q1 Results |
Flutter Entertainment PLC | Q1 Results |
Glencore PLC | Trading Statement |
Howden Joinery Group PLC | Trading Statement |
HSS Hire Group PLC | Full Year Results |
Hurricane Energy PLC | Full Year Results |
Inchcape PLC | Trading Statement |
Indivior PLC | Q1 Results |
International Personal Finance PLC | Trading Statement |
J Sainsbury PLC | Full Year Results |
Keystone Law Group PLC | Full Year Results |
Lancashire Holdings Ltd | Q1 Trading Statement |
Novacyt SA | Full Year Results |
PPHE Hotel Group Ltd | Trading Statement |
Sanderson Design Group PLC | Full Year Results |
Schroders PLC | Trading Statement |
Smith & Nephew PLC | Q1 Results |
Spectris PLC | Q1 Results |
St James's Place PLC | Trading Statement |
Standard Chartered PLC | Q1 Results |
Unilever PLC | Q1 Results |
Whitbread PLC | Full Year Results |
Copyright 2022 Alliance News Limited. All Rights Reserved. |
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:
Read moreAngle PLC - Surrey, England-based medical diagnostics company - Notes University of Maryland Marlene and Stewart Greenebaum NCI Comprehensive Cancer Institute has published results of work undertaken in preclinical models of triple-negative breast cancer. Findings show isolation of live circulating tumour cells from a simple blood draw, using Angle's Parsortix system, can provide rapid information on patient response to existing chemotherapy treatments that can target metastasis more effectively than tumour growth.
Read more